前立腺がん治療薬の世界市場2016-2020:ホルモン療法、化学療法、免疫療法、標的治療

◆英語タイトル:Global Prostate Cancer Drugs Market 2016-2020
◆商品コード:IRTNTR10968
◆発行会社(調査会社):Technavio
◆発行日:2016年11月29日
◆ページ数:91
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、前立腺がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、前立腺がん治療薬の世界市場規模及び予測、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Prostate Cancer DrugsProstate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.

Technavio’s analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Astellas Pharma
• AstraZeneca
• Johnson & Johnson
• Sanofi

[Other prominent vendors]
• Active Biotech
• ADC Therapeutics
• Advantagene
• Advaxis Pharmaceuticals
• ANI Pharmaceuticals
• ArQule
• Athenex Pharmaceuticals
• Bavarian Nordic
• Bayer HealthCare
• BHR Pharma
• BMS
• Boehringer Ingelheim
• Camurus
• Cleveland BioLabs
• CureVac
• Dendreon
• Dextech Medical
• Eisai
• Endo Pharmaceuticals
• Ferring Pharmaceutical
• Foresee Pharmaceuticals
• GlaxoSmithKline
• GTx
• Innocrin Pharmaceutical
• Inspyr Therapeutics
• Io Therapeutics
• Lidds AB
• Merck Group
• Myovant Sciences
• Northwest Biotherapeutics
• Novartis
• Nymox Pharmaceuticals
• OncoGenex
• Oncolytics Biotech
• Orion
• Pharmamar
• Progenics Pharmaceuticals
• Sotio
• Spectrum Pharmaceuticals
• Synta
• Takeda Pharmaceuticals
• Teva Pharmaceutical
• Tokai Pharmaceuticals

[Market driver]
• Physicians preference toward adopting hormonal therapies
• For a full, detailed list, view our report

[Market challenge]
• Presence of alternative treatment approaches
• For a full, detailed list, view our report

[Market trend]
• Emergence of targeted therapies and immunotherapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding disease
• Types of prostate cancer
• Diagnosis
• Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape
• Global prostate cancer therapeutics market
• Five forces analysis

PART 08: Market segmentation by therapy
• Hormonal therapy
• Chemotherapy
• Immunotherapy
• Targeted therapy

PART 09: Geographical segmentation
• Global prostate cancer drugs market by geographical segmentation 2015-2020
• Prostate cancer drugs market in Americas
• Prostate cancer drugs market in EMEA
• Prostate cancer drugs market in APAC

PART 10: Market drivers
• Physicians preference toward adopting hormonal therapies
• Development of drugs with novel mechanism of action
• Availability of large patient pool

PART 11: Impact of drivers

PART 12: Market challenges
• Presence of alternative treatment approaches
• High cost of drugs
• Adverse side-effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
Johnson & Johnson
• Astellas Pharma
• AstraZeneca
• Sanofi
• AbbVie
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global prostate cancer drugs market
Exhibit 03: Snapshot of prostate cancer
Exhibit 04: Types of prostate cancer
Exhibit 05: Main diagnostic procedures to determine presence of prostate cancer
Exhibit 06: Key buying criteria for prostate cancer drugs
Exhibit 07: Factors affecting the adoption rates of prostate cancer drugs 2015 and 2020
Exhibit 08: Pipeline analysis of key vendors in global prostate cancer drugs market
Exhibit 09: Percentage share of drug candidates by stage of development
Exhibit 10: Phase III pipeline portfolio: Global prostate cancer drugs market
Exhibit 11: Phase II pipeline portfolio: Global prostate cancer drugs market
Exhibit 12: Phase I pipeline portfolio: Global prostate cancer drugs market
Exhibit 13: Global prostate cancer therapeutics market snapshot
Exhibit 14: Analysis of global prostate cancer therapeutics market
Exhibit 15: Pipeline of global prostate cancer drugs
Exhibit 16: Global prostate cancer drugs market 2015-2020 ($ billions)
Exhibit 17: Opportunity analysis of global prostate cancer drugs market
Exhibit 18: Opportunity analysis in developed and emerging markets
Exhibit 19: Five forces analysis
Exhibit 20: Segmentation of global prostate cancer drugs market by therapy 2015
Exhibit 21: Life cycle analysis of key segments in global prostate cancer drugs market
Exhibit 22: Analysis of prostate cancer drugs market by geography
Exhibit 23: Segmentation of prostate cancer drugs market based on geography 2015 and 2020
Exhibit 24: Prostate cancer drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 25: Prostate cancer drugs market size and forecast in Americas 2015-2020 ($ billions)
Exhibit 26: Key trends across various countries in Americas
Exhibit 27: Incidence of prostate cancer in key countries of EMEA 2012
Exhibit 28: Prostate cancer drugs market size and forecast in EMEA 2015-2020 ($ billions)
Exhibit 29: Trends in prostate cancer therapeutics market in EMEA
Exhibit 30: Prostate cancer drugs market in APAC 2015-2020 ($ billions)
Exhibit 31: Key drivers and challenges in APAC
Exhibit 32: Performance of hormone therapies in 2015
Exhibit 33: Key drugs with novel mechanism of action
Exhibit 34: Potential older population with prostate cancer (65 years and above)
Exhibit 35: Impact of drivers
Exhibit 36: Alternative therapies
Exhibit 37: Costs of key prostate cancer drugs ($ thousands)
Exhibit 38: Some of the side-effects of drugs
Exhibit 39: Force field analysis of drivers and challenges in global prostate cancer drugs market
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Trend analysis in global prostate cancer drugs market
Exhibit 42: Key highlights of targeted therapies and immunotherapies
Exhibit 43: New advancements in diagnosis of prostate cancer
Exhibit 44: Key late stage pipeline candidates
Exhibit 45: Competitive structure analysis of global prostate cancer drugs market 2015
Exhibit 46: Market share analysis 2015
Exhibit 47: Performance/initiatives of existing and upcoming vendors in global prostate cancer drugs market
Exhibit 48: Competitive analysis in global prostate cancer therapeutics market
Exhibit 49: Market penetration of various prostate cancer drug manufacturers worldwide 2015
Exhibit 50: Regional analysis of vendors in global prostate cancer drugs market
Exhibit 51: Johnson & Johnson: Key highlights
Exhibit 52: Johnson & Johnson: Strength assessment
Exhibit 53: Johnson & Johnson: Strategy assessment
Exhibit 54: Johnson & Johnson: Opportunity assessment
Exhibit 55: Johnson & Johnson: YoY revenue comparison of Zytiga (Global) 2013-2015 ($ billions)
Exhibit 56: Astellas Pharma: Key highlights
Exhibit 57: Astellas Pharma: Strength assessment
Exhibit 58: Astellas Pharma: Strategy assessment
Exhibit 59: Astellas Pharma: Opportunity assessment
Exhibit 60: Astellas Pharma: YoY revenue comparison of Xtandi 2014-2015 ($ billions)
Exhibit 61: AstraZeneca: Key highlights
Exhibit 62: AstraZeneca: Strength assessment
Exhibit 63: AstraZeneca: Strategy assessment
Exhibit 64: AstraZeneca: Opportunity assessment
Exhibit 65: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
Exhibit 66: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 67: AstraZeneca: YoY revenue and growth rate of Casodex 2013-2015 ($ millions)
Exhibit 68: AstraZeneca: Geographic segmentation of Zoladex 2015
Exhibit 69: Sanofi: Key highlights
Exhibit 70: Sanofi: Strength assessment
Exhibit 71: Sanofi: Strategy assessment
Exhibit 72: Sanofi: Opportunity assessment
Exhibit 73: Sanofi: YoY revenue and growth rate of Jevtana 2013-2015 ($ millions)
Exhibit 74: Sanofi: YoY revenue and growth rate of Taxotere 2013-2015 ($ millions)
Exhibit 75: AbbVie: Key highlights
Exhibit 76: AbbVie: Strength assessment
Exhibit 77: AbbVie: Strategy assessment
Exhibit 78: AbbVie: Opportunity assessment
Exhibit 79: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)



【掲載企業】

AbbVie, Astellas Pharma, AstraZeneca, Johnson & Johnson, Sanofi, Active Biotech, ADC Therapeutics, Advantagene, Advaxis Pharmaceuticals, ANI Pharmaceuticals, ArQule, Athenex Pharmaceuticals, Bavarian Nordic, Bayer HealthCare, BHR Pharma, BMS, Boehringer Ingelheim, Camurus, Cleveland BioLabs, CureVac, Dendreon, Dextech Medical, Eisai, Endo Pharmaceuticals, Ferring Pharmaceutical, Foresee Pharmaceuticals, GlaxoSmithKline, GTx, Innocrin Pharmaceutical, Inspyr Therapeutics, Io Therapeutics, Lidds AB, Merck Group, Myovant Sciences, Northwest Biotherapeutics, Novartis, Nymox Pharmaceuticals, OncoGenex, Oncolytics Biotech, Orion, Pharmamar, Progenics Pharmaceuticals, Sotio, Spectrum Pharmaceuticals, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Tokai Pharmaceuticals.

【レポートのキーワード】

前立腺がん治療薬、前立腺がんホルモン療法、前立腺がん化学療法、前立腺がん免疫療法、前立腺がん標的治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[前立腺がん治療薬の世界市場2016-2020:ホルモン療法、化学療法、免疫療法、標的治療]販売に関する免責事項
★調査レポート[前立腺がん治療薬の世界市場2016-2020:ホルモン療法、化学療法、免疫療法、標的治療]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆